J. W. Coons Advisors LLC Trims Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

J. W. Coons Advisors LLC lessened its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.2% in the fourth quarter, Holdings Channel reports. The fund owned 1,477 shares of the medical equipment provider’s stock after selling 97 shares during the quarter. J. W. Coons Advisors LLC’s holdings in Intuitive Surgical were worth $771,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently bought and sold shares of ISRG. Berbice Capital Management LLC purchased a new stake in Intuitive Surgical during the fourth quarter valued at $26,000. MidAtlantic Capital Management Inc. purchased a new stake in Intuitive Surgical during the third quarter valued at $33,000. Decker Retirement Planning Inc. purchased a new stake in Intuitive Surgical during the fourth quarter valued at $36,000. Capital Performance Advisors LLP purchased a new stake in Intuitive Surgical in the third quarter worth about $38,000. Finally, Sierra Ocean LLC purchased a new stake in Intuitive Surgical in the fourth quarter worth about $40,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, CFO Jamie Samath sold 108 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $542.06, for a total transaction of $58,542.48. Following the sale, the chief financial officer now directly owns 8,757 shares in the company, valued at $4,746,819.42. This represents a 1.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Myriam Curet sold 408 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $589.75, for a total value of $240,618.00. Following the sale, the executive vice president now owns 353 shares in the company, valued at approximately $208,181.75. This trade represents a 53.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 6,348 shares of company stock valued at $3,587,582. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Trading Down 2.4 %

Shares of Intuitive Surgical stock opened at $591.79 on Monday. The stock has a 50 day moving average of $565.45 and a 200 day moving average of $525.60. Intuitive Surgical, Inc. has a 12 month low of $364.17 and a 12 month high of $616.00. The firm has a market cap of $210.78 billion, a PE ratio of 92.32, a PEG ratio of 5.85 and a beta of 1.39.

Analyst Ratings Changes

A number of analysts have commented on ISRG shares. Erste Group Bank upgraded Intuitive Surgical from a “hold” rating to a “buy” rating in a research report on Tuesday, November 19th. Stifel Nicolaus upped their price target on Intuitive Surgical from $525.00 to $610.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. BTIG Research upped their price target on Intuitive Surgical from $535.00 to $561.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. JPMorgan Chase & Co. upped their price target on Intuitive Surgical from $575.00 to $675.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Finally, Wells Fargo & Company upped their price target on Intuitive Surgical from $630.00 to $687.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $613.10.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.